New drug aims to tame aggressive pancreatic cancer before surgery
NCT ID NCT06203821
Summary
This early-stage study is testing if adding an experimental drug called NP137 to standard chemotherapy (FOLFIRINOX) before and after surgery can help control pancreatic cancer. The goal is to see if NP137 can change the tumor's behavior to make it less aggressive and potentially improve outcomes. The study will enroll about 25 adults with pancreatic cancer that surgeons believe can be removed.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Rochester
Rochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.